Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Themis Bioscience GmbH

www.themisbio.com

Latest From Themis Bioscience GmbH

Deal Watch: Themis Leverages Measles Vector Platform In Collaboration With Merck & Co.

In its first big pharma deal, Austrian biotech will develop experimental vaccines for Merck against an undisclosed target. Innovent licenses Chinese rights to Lilly diabetes candidate, while Novartis gets option to Iconic’s preclinical ophthalmology program.

Deals Business Strategies

Finance Watch: Third Rock Raises $770m To Launch Up To 12 New Companies

The VC firm known for its new company formation efforts will launch 10-12 biopharma, device and diagnostic ventures with its fifth fund. Also, EpimAb raises a $74m series B round, three more drug developers join the IPO queue and Amicus leads recent follow-on offerings.

Financing StartUps and SMEs

MSF Attacks Vaccines Collaboration Over ‘Toothless’ New Equitable Access Policy

The Coalition for Epidemic Preparedness Innovationhas come under attack from Médecins sans Frontières over its revised equitable vaccines access policy, which the NGO claims has been watered down at the behest of the pharmaceutical industry.
Vaccines Regulation

Finance Watch: Not Everyone Can Go Public, But Biopharma IPOs Are Using Multiple Markets

Not every drug developer can go public, but biopharma IPOs are launching in multiple markets, including Moderna's prospective $500m US offering and Innovent's $421m Hong Kong IPO. Also, Sarepta prices a $500m FOPO and Omeros sells $210m in notes.

Financing Asia Pacific
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Austria
  • Parent & Subsidiaries
  • Themis Bioscience GmbH
  • Senior Management
  • Erich Tauber, MD, CEO
    David A Maier, PhD, CFO
    Philippe Dro, CBO
    Katrin Ramsauer, PhD, CSO
  • Contact Info
  • Themis Bioscience GmbH
    Phone: (43) 1 236 7151
    Muthgasse 11/2
    Vienna, 1190
    Austria
Advertisement
Advertisement
UsernamePublicRestriction

Register